Antiretroviral Drugs for Millions

  • Allan Ronald
  • Elly Katabira
  • Merle Sande
Part of the Infectious Disease book series (ID)


Highly active antiretroviral therapies have markedly altered the illness course of approx 1.3 million people since these therapies became widely prescribed in 1997. However, approx 80% of individuals who are on treatment are residents of industrialized countries of the world, where fewer than 10% of the HIV-infected individuals make their home. In contrast, in December 2004, in sub-Saharan Africa, less than 300,000 individuals are taking antiretroviral treatment (ARV) in an HIV-infected population of approx 26 million. This is substantially less than 1 patient out of 50 who meet the “Western” criteria for treatment.


Malaria Fluconazole Poss Tert Tenofovir 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Egger M, May M, Chene G, et al. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002:360; 119–128.PubMedCrossRefGoogle Scholar
  2. 2.
    Kityo Mutuluuza C, Walker S, Kaleebu P, et al. Short-term virologic response to a triple nucleoside/nucleotide analogue regimen in adults with HIV infection in Africa within the DART Trial. 12th Conference on Retroviruses and opportunistic Infections; Boston, MA; 2005.Google Scholar
  3. 3.
    Helfand WH, Lazarus J, Theerman P. Ignore AIDS and it will bury the rest of you. Amer J Pub H alth 2000:90; 1028.CrossRefGoogle Scholar
  4. 4.
    Hogg R, Cahn P, Katabira E, et al. Time to act: global apathy towards HIV/AIDS is a crime against humanity. Lancet 2002: 360; 1710–1711.PubMedCrossRefGoogle Scholar
  5. 5.
    Chen L, Evans T, Anand S, et al. Human resources for health: overcoming the crisis. Lancet 2004: 364; 1984–1990.PubMedCrossRefGoogle Scholar
  6. 6.
    Farmer P, Leandre F, Mukherjee JS, et al. Community-based approaches to HIV treatment in resource-poor settings. Lancet 2001: 322; 1087–1088.Google Scholar
  7. 7.
    Blower S. Calculating the consequences: HAART and risky sex. AIDS 2001: 15; 1309–1310.PubMedCrossRefGoogle Scholar
  8. 8.
    Moses S, Plummer FA, Ngugi EN, Nagelkerke NJ, Anzala Ao, Ndinya-Achola Jo. Controlling HIV in Africa: effectiveness and cost of an intervention in a high-frequency STD transmitter core group. AIDS 1991: 5; 407–411.PubMedCrossRefGoogle Scholar
  9. 9.
    The Voluntary HIV-1 Counseling and Testing Efficacy Study Group. Efficacy of voluntary HIV-1 counseling and testing in individuals and couples in Kenya, Tanzania, and Trinidad: a randomized trial. Lancet 2000; 356: 103–112.Google Scholar
  10. 10.
    Casseb J, Pereira LC Jr, Silva GL, Medeiros LA. Decreasing mortality and mor-bidity in adult AIDS patients from 1995 to1997 in Sao Paula, Brazil. AIDS Patient Care STDS 1999; 13: 213–214.PubMedCrossRefGoogle Scholar
  11. 11. accessed october 9, 2005.
  12. 12.
    Byakika-Tusiime J, oyugi JH, Tumwikirize WA, Katabira ET, Mugyenyi PN, Bangsberg DR. Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. Int J STD and AIDS 2005: 16; 38–41.CrossRefGoogle Scholar
  13. 13.
    oyugi JH, Byakika-Tusiime J, Charlebois ED. Multiple Validated Measures of Adherence Indicate High Levels of Adherence to Generic HIV Antiretroviral Therapy in a Resource-Limited Setting. J Acquir Immune Defic Syndr. 2004 Aug 15; 36(5): 1100–1102.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2006

Authors and Affiliations

  • Allan Ronald
    • 1
  • Elly Katabira
    • 2
  • Merle Sande
    • 3
  1. 1.Infectious DiseasesSt. Boniface HospitalWinnipegCanada
  2. 2.Makerere UniversityKampalaUganda
  3. 3.Department of MedicineUniversity of UtahSalt Lake City

Personalised recommendations